Video
Video di 5 minuti
30 aprile 2025
COMUNITÀ E SALUTE GLOBALE
prod:prod_dcx-login
L’esigenza
- In 2022, only 43% of the total estimated multidrug-resistant Tuberculosis (MDR-TB) incident cases were diagnosed and enrolled on treatment regimen1
- Only 47% of the total notified MDR-TB cases were tested for resistance to fluoroquinolones1
- Increase access to rapid and extended drug resistance profiling for all TB-positive cases to rule out MDR/pre-XDR^ TB2
1 World Health Organization Tuberculosis Report 2023--https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/tb-disease-burden/1-3-drug-resistant-tb. Accessed January 2024.
2 Global Plan to End TB, STOP TB Report- https://omnibook.com/api/export/1.0/dc664b3a-14b4-4cc0-8042-ea8f27e902a6/-1/0/pdf^ Pre-XDR: Pre-Extensive Drug Resistant TB
^ Pre-XDR: Pre-Extensive Drug Resistant TB
2 Global Plan to End TB, STOP TB Report- https://omnibook.com/api/export/1.0/dc664b3a-14b4-4cc0-8042-ea8f27e902a6/-1/0/pdf^ Pre-XDR: Pre-Extensive Drug Resistant TB
^ Pre-XDR: Pre-Extensive Drug Resistant TB
La soluzione
The Xpert MTB/XDR test enables rapid molecular DST. When combined with the frontline Xpert MTB/RIF Ultra test, it detects mutations associated with resistance to isoniazid (INH), fluoroquinolones (FLQ), second-line injectable drugs (SLIDs), and ethionamide (ETH) in a single test.
- Fast time to result for molecular DST
- Risultati in <90 minuti
- Same easy-to-use process as the Xpert MTB/RIF Ultra test
- Eseguibile sulle piattaforme GeneXpert® esistenti dotate di moduli a 10 colori
L’impatto
- Upfront molecular DST for TB‑positive cases supports timely treatment planning
- Helps supports expanded access to drug‑resistance testing for MDR and pre‑XDR TB.3
- The Xpert MTB/XDR assay provides the capability to differentiate between high and low-level resistance to INH and FLQ, which which provides additional information that may support resistance interpretation alongside clinical findings.4
3 Adam Penn-Nicholson et al. 2022 https://www.medrxiv.org/content/10.1101/2021.05.06.21256505v1.full.pdf
4 L Saderi, et al. 2022 https://www.archbronconeumol.org/es-pdf-S0300289622004987
4 L Saderi, et al. 2022 https://www.archbronconeumol.org/es-pdf-S0300289622004987
